You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Dow
Harvard Business School
McKesson
Johnson and Johnson
Medtronic
Colorcon

Last Updated: October 1, 2020

DrugPatentWatch Database Preview

OCTREOTIDE ACETATE Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which patents cover Octreotide Acetate, and what generic alternatives are available?

Octreotide Acetate is a drug marketed by Fresenius Kabi Usa, Heritage Pharms Inc, Sagent Pharms Inc, Sun Pharm Inds, Teva Pharms Usa, West-ward Pharms Int, Wockhardt Usa, and Mylan Institutional. and is included in eighteen NDAs.

The generic ingredient in OCTREOTIDE ACETATE is octreotide acetate. There are twenty drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the octreotide acetate profile page.

US ANDA Litigation and Generic Entry Outlook for Octreotide Acetate

A generic version of OCTREOTIDE ACETATE was approved as octreotide acetate by WEST-WARD PHARMS INT on April 8th, 2005.

  Start Trial

Drug patent expirations by year for OCTREOTIDE ACETATE
Drug Prices for OCTREOTIDE ACETATE

See drug prices for OCTREOTIDE ACETATE

Recent Clinical Trials for OCTREOTIDE ACETATE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Roswell Park Cancer InstitutePhase 1
NeuroEndocrine Tumor Research Foundation (NETRF)Phase 1
Ono Pharmaceutical Co. LtdPhase 1

See all OCTREOTIDE ACETATE clinical trials

Pharmacology for OCTREOTIDE ACETATE
Medical Subject Heading (MeSH) Categories for OCTREOTIDE ACETATE
Paragraph IV (Patent) Challenges for OCTREOTIDE ACETATE
Tradename Dosage Ingredient NDA Submissiondate
SANDOSTATIN INJECTABLE;INJECTION octreotide acetate 019667 2008-01-17

US Patents and Regulatory Information for OCTREOTIDE ACETATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Wockhardt Usa OCTREOTIDE ACETATE PRESERVATIVE FREE octreotide acetate INJECTABLE;INJECTION 090985-001 May 11, 2011 DISCN No No   Start Trial   Start Trial   Start Trial
Mylan Institutional OCTREOTIDE ACETATE (PRESERVATIVE FREE) octreotide acetate INJECTABLE;INJECTION 079198-001 Feb 10, 2011 AP RX No No   Start Trial   Start Trial   Start Trial
Wockhardt Usa OCTREOTIDE ACETATE octreotide acetate INJECTABLE;INJECTION 090986-002 May 11, 2011 DISCN No No   Start Trial   Start Trial   Start Trial
Mylan Institutional OCTREOTIDE ACETATE (PRESERVATIVE FREE) octreotide acetate INJECTABLE;INJECTION 079198-002 Feb 10, 2011 AP RX No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Merck
Harvard Business School
Johnson and Johnson
Dow
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.